NV-HHV-101
/ NanoViricides
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 15, 2022
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 – Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready
(Digital Journal)
- "NanoViricides is one of a few biopharma companies that has its own cGMP-compliant manufacturing facility...This production capacity is anticipated to be sufficient for first-in-human use in the current SARS-CoV-2 pandemic for our anti-coronavirus drug in development, as well as for the anticipated clinical trials of NV-HHV-101 skin cream for the treatment of shingles."
Clinical • Herpes Zoster • Infectious Disease • Varicella Zoster
1 to 1
Of
1
Go to page
1